Ron Squarer has served as Chief Executive Officer and a member of the Array Board of Directors since April 2012. Mr. Squarer has extensive commercial, development and executive leadership expertise from a greater than two decade career in the biopharmaceutical industry. Prior to this, Mr. Squarer held positions of increasing responsibility with Hospira Inc., a global pharmaceutical and medical device company, most recently serving as Senior Vice President, Chief Commercial Officer, where he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007. Prior to Mayne Pharma, Mr. Squarer held senior management roles at both Pfizer, Inc., and at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe. Mr. Squarer currently serves as a member of the Board of Directors of Retrophin, Inc. Mr. Squarer holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor’s degree in biochemistry from the University of California, Berkeley.
Mr. Haddock joined Array as Chief Financial Officer in July 2016. He has more than 15 years of financial and operational experience in the biopharmaceutical industry. Mr. Haddock held leadership positions of increasing responsibility at Bristol-Myers Squibb, a global pharmaceutical company with a strong focus on immuno-oncology therapies. During that time, he served in variety of accounting, planning, commercial, analytical and business development capacities for high-growth business units, including Head of Finance for the Worldwide Commercialization and Medical teams. Mr. Haddock also served as Executive Director for the U.S. Pharmaceutical unit, where he focused on designing and implementing a completely new business model and operations to capitalize on future product portfolio changes and market developments. Mr. Haddock most recently served as Chief Financial Officer and Chief Operating Officer of BERG Health, an oncology focused research, diagnostics and development company, where he oversaw the implementation of financial and operational processes, procedures and policies to transform and scale the company’s practices as it planned for growth and corporate evolution. Mr. Haddock earned his undergraduate degree in accountancy from Illinois State University and is a Certified Management Accountant. He holds an MBA from Washington University in St. Louis where he completed the Executive Program.
Mr. Moore has served as Vice President and General Counsel since May 2002 and as Secretary since October 2002. Prior to joining Array, Mr. Moore was an associate for three years with the law firm Wilson Sonsini Goodrich & Rosati, where he negotiated transactions involving technology, intellectual property matters and products. Prior to that, Mr. Moore was an Associate with the law firms Kenyon & Kenyon and Arnold White & Durkee, where he focused on intellectual property matters. He currently serves on the Board of Directors of Nivalis Therapeutics (Nasdaq: NVLS). Mr. Moore received a J.D. from the University of North Carolina at Chapel Hill, an M.S. in Biochemistry from the University of Illinois at Urbana-Champaign and a B.S. in Chemistry from the University of North Carolina at Chapel Hill.
Dr. Victor Sandor has served as Chief Medical Officer since September 2014. Dr. Sandor has more than a decade of experience in the pharmaceutical and biotechnology industries. Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation. In this role, he was instrumental in the development, approval and commercialization of Jakafi® (ruxolitinib), the first JAK inhibitor, while leading clinical development, clinical operations, medical affairs and biostatistics across the entire portfolio, including responsibility for several novel mechanisms including PI3K, c-Met and IDO1 inhibitors. Prior to Incyte, Dr. Sandor was Vice President and Chief Medical Officer for oncology at Biogen Idec. He previously held positions of increasing responsibility in oncology product development at AstraZeneca, where he played an important role in the registration of Arimidex® (anastrozole) for adjuvant use, the development of Faslodex® (fulvestrant injection), and the development of several early stage programs through proof of concept. Dr. Sandor received his MD CM from McGill University in Montreal, Canada, and completed his Fellowship in Medical Oncology at the National Institutes of Health in Bethesda, Maryland.
Andrew Robbins has served as Chief Operating Officer since March 2015 and previously served as Senior Vice President of Commercial Operations since July 2012. Mr. Robbins has extensive commercial, development and strategic leadership expertise from a 17-year career in the pharmaceutical industry, with a specific focus on oncology/hematology products. Most recently he was at Hospira, Inc. where he served as General Manager/Vice President of the U.S. Alternate Site business unit, focused on the sales of pharmaceuticals and medical devices to outpatient oncology, surgery, pain and dialysis customers. In this role, he led a team of approximately 100 employees, including a national sales force, to deliver over $400 million in annual revenue. Prior to this, he was Vice President of Corporate Development and was responsible for global branded pharmaceutical marketing and business development, research and development portfolio prioritization, global strategy and corporate venture investing. During his tenure, he designed and executed a strategy to build a late-stage hematology/oncology and acute pain pipeline via licensing and acquisition. Mr. Robbins also served on the Board of Directors for three venture-backed healthcare companies, two of which were focused on innovative hematology/oncology products. Before Hospira, Mr. Robbins was a commercial leader within Pfizer’s oncology unit, responsible for shepherding a portfolio of 12 preclinical and clinical stage products through development using a “fast-to-patient” approach. Several of these products, including Sutent® (sunitinib), Inlyta® (axitinib) and Xalkori® (crizotinib) have been commercialized. Mr. Robbins holds an MBA from the Kellogg School of Management, Northwestern University and a bachelor's degree from Swarthmore College.
Dr. Nicholas A. Saccomano has served as Chief Scientific Officer since May 2014. Dr. Saccomano is a seasoned leader with 30 years of experience in pharmaceutical and biotechnology research and development, with expertise in discovery research, clinical development, portfolio strategy, technology and clinical candidate licensing, and scientific partnering. Dr. Saccomano most recently served as Chief Technology Officer at SomaLogic, Inc. and as Chief Scientific Officer at Bend Research Inc. While at Pfizer Inc., Dr. Saccomano held positions of increasing responsibility, including Senior Vice President in the R&D organization and Vice President of Discovery Technology. As head of discovery technology, he managed and developed a diverse set of enabling technologies used broadly across the drug discovery pipeline. During his tenure, he also directed medicinal sciences, drug discovery and strategic alliances. Dr. Saccomano obtained his Ph.D. in chemistry from Columbia University under the direction of Professor Gilbert Stork.
Ms. Kimberly Pope has served as Vice President of Human Resources since January 2016. Ms. Pope has extensive Human Resource, business and leadership experience in the healthcare and technology industries, including 16 years with Abbott Laboratories and Hospira Inc. She started at Abbott Laboratories in the Talent Acquisition group and later transitioned to Hospira. At Hospira, Ms. Pope held leadership positions of increasing responsibility including Director of Human Resources for Global Marketing, for Global Information Technology and for Global Operations. In the Operations role, she was responsible for the HR business partner relationships for the Global API Pharmaceutical business, Program Management, Global Engineering, Manufacturing Science and Technology and the Technical Professional Development Program. In addition, her business strengths allowed her to play a key role in a major acquisition in India, including the building of the largest injectable medicine facility in the world. Most recently, Ms. Pope was Group Vice President, Human Resources at IDEX Corporation, a global leader in applied engineering solutions, specializing in health and science technologies, among other diversified products. In her role, she supported a global team of 900 associates, across 11 sites where she had responsibility for Talent Management, Talent Acquisition, Organizational Effectiveness and driving culture change throughout the business. Ms. Pope holds a Bachelor of Business Administration degree from the University of Iowa and is a Senior Professional in Human Resources from the Human Resource Certification Institute.